Abstract：
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown etiology. Currently, drugs used to treat IPF in clinical practice exhibit severe side effects and limitations. To address these issues, this paper discusses the therapeutic effects of preclinical targeted drugs (such as STAT3 and TGF-β/Smad pathway inhibitors, chitinase inhibitors, PI3K and phosphodiesterase inhibitors, etc.) and natural products on IPF. Through a summary of current research progress, it is found that natural products possess multitarget effects, stable therapeutic efficacy, low side effects, and nondrug dependence. Furthermore, we discuss the significant prospects of natural product molecules in combating fibrosis by influencing the immune system, expecting that current analytical data will aid in the development of new drugs or the investigation of active ingredients in natural products for potential IPF treatments in the future.
摘要：
特发性肺纤维化(IPF)是一种病因不明的慢性间质性肺病。目前,在临床实践中用于治疗IPF的药物表现出严重的副作用和局限性。为了解决这些问题,本文讨论了临床前靶向药物(如STAT3和TGF-β/Smad通路抑制剂,几丁质酶抑制剂，PI3K和磷酸二酯酶抑制剂，等。)和IPF上的天然产物。通过对当前研究进展的总结,发现天然产物具有多目标效应，稳定的治疗效果，副作用低,和非药物依赖。此外，我们讨论了天然产物分子通过影响免疫系统来对抗纤维化的重要前景，预计当前的分析数据将有助于新药的开发或天然产品中的活性成分的研究，以在未来潜在的IPF治疗。
